Lucid Diagnostics Inc (NASDAQ: LUCD) is 52.07% higher on its value in year-to-date trading and has touched a low of $0.68 and a high of $1.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LUCD stock was last observed hovering at around $1.39 in the last trading session, with the day’s loss setting it -0.14%.
Currently trading at $1.25, the stock is -4.43% and -7.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.98 million and changing -10.43% at the moment leaves the stock 17.49% off its SMA200. LUCD registered 38.66% gain for a year compared to 6-month gain of 24.70%. The firm has a 50-day simple moving average (SMA 50) of $1.3529 and a 200-day simple moving average (SMA200) of $1.057775.
The stock witnessed a -3.49% loss in the last 1 month and extending the period to 3 months gives it a -7.09%, and is -21.70% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.82% over the week and 6.27% over the month.
Lucid Diagnostics Inc (LUCD) has around 72 employees, a market worth around $126.50M and $4.17M in sales. Profit margin for the company is -1699.86%. Distance from 52-week low is 82.82% and -30.83% from its 52-week high.
The EPS is expected to grow by 34.18% this year.
Lucid Diagnostics Inc (LUCD) Top Institutional Holders
53.0 institutions hold shares in Lucid Diagnostics Inc (LUCD), with institutional investors hold 14.94% of the company’s shares. The shares outstanding are 84.37M, and float is at 37.89M with Short Float at 4.70%. Institutions hold 9.78% of the Float.
The top institutional shareholder in the company is LUMINUS MANAGEMENT LLC with over 0.73 million shares valued at $0.6 million. The investor’s holdings represent 1.6124% of the LUCD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 0.56 million shares valued at $0.46 million to account for 1.2461 of the shares outstanding. The other top investors are GEODE CAPITAL MANAGEMENT, LLC which holds 0.2 million shares representing 0.454% and valued at over $0.17 million, while NANTAHALA CAPITAL MANAGEMENT, LLC holds 0.2807 of the shares totaling 0.13 million with a market value of $0.1 million.
Lucid Diagnostics Inc (LUCD) Insider Activity
The most recent transaction is an insider purchase by Matheis Dennis, the company’s Director. SEC filings show that Matheis Dennis bought 187,098 shares of the company’s common stock on May 20 ’25 at a price of $1.29 per share for a total of $0.24 million. Following the purchase, the insider now owns 0.19 million shares.
Lucid Diagnostics Inc disclosed in a document filed with the SEC on May 21 ’25 that Matheis Dennis (Director) bought a total of 129,684 shares of the company’s common stock. The trade occurred on May 21 ’25 and was made at $1.32 per share for $0.17 million. Following the transaction, the insider now directly holds 0.32 million shares of the LUCD stock.
Still, SEC filings show that on May 22 ’25, Matheis Dennis (Director) acquired 33,218 shares at an average price of $1.32 for $43795.0. The insider now directly holds 350,000 shares of Lucid Diagnostics Inc (LUCD).
